Biofutures International plc Temporary Suspension (1500T)
10 12월 2012 - 10:00PM
UK Regulatory
TIDMBIP
RNS Number : 1500T
Biofutures International plc
10 December 2012
10 December 2012
Biofutures International Plc
("Biofutures" or the "Company")
Proposed Acquisition of Platinum Nanochem Sdn. Bhd.
Suspension of Trading on AIM
The board of directors of Biofutures ("Board") is pleased to
announce that it has entered into a conditional share sale
agreement ("Agreement") to acquire Platinum Nanochem Sdn. Bhd.
("Platinum") (the "Acquisition"). Platinum is a Malaysian based
company, which utilizes nanotechnology for the production of
speciality chemicals and materials from renewable sources.
The two technologies held by Platinum are the SimPlat(TM)
technology and the Catalyx(TM) technology. The SimPlat(TM)
technology enables the production of a wide variety of intermediate
and specialty chemicals from liquid waste and process residue
materials. The Catalyx(TM) technology enables the production of
graphitic nanomaterials. These include graphene nanoplatelets, a
performance enabling nanomaterial, which is known for being
exceptionally lightweight. The graphene nanoplatelets possess a
wide range of intrinsic properties, from enhanced electrical and
thermal conductivity to exceptional mechanical load bearing
capacity and performance, that can be transferred into other
existing materials creating higher value products possessing
significantly enhanced property values.
Platinum is presently generating revenue from its operations,
producing green fuel additives for the oil and gas sector which is
set for capacity expansion. Platinum is currently focused on (1)
expanding into the oilfield chemicals markets through the
production of graphene-enhanced chemicals; and (2) developing
alternative applications of graphene through strategic
partnerships.
The Board believes that the Acquisition offers a way forward for
the Company to leverage on its existing assets to revitalize the
current position of the Company and enhance shareholders'
value.
The Acquisition will constitute a reverse takeover under AIM
Rule 14 and hence is conditional upon the publication of an
admission document and the approval of Biofutures' shareholders at
a general meeting. Biofutures expects to convene the general
meeting and complete the transaction before the end of first
quarter of 2013. Accordingly, trading in the Company's shares will
be temporarily suspended until such time as it publishes an
admission document for the enlarged group.
For further information, please contact:
Biofutures International plc Tel: + 603 6203 5136
Joe Wong, Chief Executive Officer
www.biofuturesplc.com
Daniel Stewart & Company plc Tel: + 44 (0) 20 7776 6550
Antony Legge / Emma Earl
www.danielstewart.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
SUSEAAAEFFDAFFF
Biofutures (LSE:BIP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Biofutures (LSE:BIP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024